Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects - Trial NCT06159452
Access comprehensive clinical trial information for NCT06159452 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sanofi and is currently Completed. The study focuses on Rheumatoid Arthritis. Target enrollment is 53 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sanofi
Timeline & Enrollment
Phase 1
Jul 09, 2010
Dec 21, 2010
Primary Outcome
Number of participants reporting injection site reactions
Summary
Primary objective:
 
 To determine the tolerability of different SAR153191 drug products that differ with respect
 to manufacturing processes and formulation, at different concentrations and doses, after
 administration of single subcutaneous doses to healthy male subjects.
 
 Secondary objectives:
 
 To determine the pharmacokinetic profile of the different SAR153191 drug products
 administered subcutaneously.
 
 To assess the safety of the different SAR153191 drug products administered subcutaneously.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06159452
Non-Device Trial